1. Chapter 49: Bisphosphonates for Postmenopausal Osteoporosis
Socrates E. Papapoulos

2. From the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th Edition.
Figure 1
Figure 1 (Left) Structure of pyrophosphate and geminal bisphosphonates. (Right) Structures of clinically used bisphosphonates (acid forms are depicted).
Figure 1 (Left) Structure of pyrophosphate and geminal bisphosphonates. (Right) Structures of clinically used bisphosphonates (acid forms are depicted).
© 2008 American Society for Bone and Mineral Research

3. From the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th Edition.
Figure 2
Figure 2 Schematic presentation of effects of bisphosphonates on bone metabolism and strength in osteoporosis.
Figure 2 Schematic presentation of effects of bisphosphonates on bone metabolism and strength in osteoporosis.
© 2008 American Society for Bone and Mineral Research

4. From the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th Edition.
Figure 3
Figure 3 Incidence of fractures in patients with osteoporosis treated with daily oral placebo (open bars) or bisphosphonate (closed bars). PAM, pamidronate; RIS 1, risedronate (VERT multinational study); CLO, clodronate; RIS 2, risedronate (VERT North America study); ALN 1, alendronate (FIT 1 study); IBN, ibandronate (BONE study); ALN 2, alendronate (FIT 2 study).
Figure 3 Incidence of fractures in patients with osteoporosis treated with daily oral placebo (open bars) or bisphosphonate (closed bars). PAM, pamidronate; RIS 1, risedronate (VERT multinational study); CLO, clodronate; RIS 2, risedronate (VERT North America study); ALN 1, alendronate (FIT 1 study); IBN, ibandronate (BONE study); ALN 2, alendronate (FIT 2 study).
© 2008 American Society for Bone and Mineral Research